RxSight (RXST) Q3 2026 earnings review
RxSight locks in Alcon cash, but lens sales keep falling
RxSight, a maker of cataract lenses that doctors adjust with light after surgery, lost more eye-clinic business while securing its partnership cash. Product sales fell 19% from a year ago as doctors tested rival implants and used about 6.6 lenses a month per machine by our math, down from 8.0 a year earlier. Unsold stock forced inventory write-downs that cut gross margin by six percentage points, though collecting $60 million from Alcon lifted cash to $255 million.
| Product sales | $24.5M -19.1% from a year ago |
|---|---|
| LAL lens implants sold | 23,128 -11.2% from a year ago |
| Gross margin | 73.6% -6.3 percentage points from a year ago |
| Cash and short-term investments | $254.7M includes $60M Alcon payment |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because passing Alcon's four-month cancellation deadline removes the cash risk, while the core lens business keeps shrinking at the same pace. Chief executive Aziz Mottiwala cut core staff and is nearly doubling the U.S. sales force to win back clinic usage. The bad news: operating costs still equal 149% of product sales by our math, and management provides no financial outlook until early 2027.
The question now is whether falling lens usage per machine is a temporary distraction from rival product launches or permanent share loss. If the problem is weak sales coverage, doubling the sales team should lift lens orders during the busy fourth quarter; if rivals have a better lens, the expanded team will only raise costs. Fourth-quarter lens volume and the return of an annual forecast in early 2027 will tell.
🐂 Bull Case
Alcon Kept the Deal Past the Refund Deadline
RxSight makes eye lenses that doctors can adjust with light after cataract surgery. In June, it licensed this technology to Alcon, a major eye-care group, for $60 million upfront and future royalties. Because Alcon had four months to walk away and demand $50 million back, the biggest near-term risk was a cancellation.
The medical-device maker collected the $60 million in the third quarter and confirmed that "the initial 120-day period under the agreement now complete". Because the deadline passed in late October, the $50 million refund liability on the September balance sheet stays with the business.
What to watch: how much of that $50 million liability moves into fourth-quarter revenue. Management previously said the full year would bring $30 million to $40 million in license sales, which by our math leaves $23 million to $33 million for the fourth quarter.
A Bigger Sales Force Targets Existing Clinics
Because clinics are buying fewer new light-delivery machines, RxSight wants doctors who already own a machine to use its lenses in more surgeries. Chief executive Aziz Mottiwala hired two new commercial leaders this quarter, naming Taryn Conway chief commercial officer and Frank Shields executive vice president of sales.
The cataract-lens maker is also "nearly doubling its sales force to support deeper customer engagement and enhanced practice support". This matters because each lens sells for nearly $1,000, so getting existing clinics to implant one or two extra lenses a month is the fastest way to stop the revenue slide.
What to watch: lens volume in the fourth quarter, when cataract surgeries normally pick up. A sequential rise above last fourth quarter's 28,611 lenses would show the larger sales team is winning back clinic time.
🐻 Bear Case
Doctors Used Fewer Lenses per Machine Again
RxSight sells two products: the Light Delivery Device (LDD), a machine that shines ultraviolet light into the eye, and the Light Adjustable Lens (LAL), the implant doctors adjust with that machine. Even as Mottiwala said his team "made progress across key long-term growth initiatives", demand at clinics kept shrinking because of "ongoing competitive pressures" from rival lenses.
- LAL implants sold: 23,128 units, down 11.2% from a year ago and down 7.2% from last quarter
- Monthly lenses used per machine: 6.6 by our math, down from 7.2 last quarter and 8.0 a year ago
- Product sales: $24.5 million, down 19.1% from a year ago
Usage per machine has now fallen for six straight quarters. Because doctors are testing competing lenses, each installed machine brings in less recurring revenue than it did a year ago.
What to watch: monthly lens usage per machine once the quarterly filing gives the new machine count. Another drop below 6.6 lenses a month would prove rival implants are taking permanent share rather than just temporary trials.
Unsold Inventory Cut Six Points Off Gross Margin
When lens and machine sales fall faster than factory output, unsold stock piles up and each unit carries more overhead. RxSight's gross margin dropped 6.3 percentage points from a year ago to 73.6%, because the cost of making its products rose 6.2 percentage points of revenue to 26.4%.
The company blamed "an increase in inventory reserves and higher inventory costs for LAL and LDD". Meanwhile, inventory on the balance sheet rose 36.8% from a year ago to $39.6 million, up another $2.5 million from June. Writing off aging stock will keep hurting margins until sales match production.
What to watch: finished-goods inventory and write-down reserves in the quarterly filing. A growing reserve would mean unsold lenses at clinics are expiring before doctors use them.
Operating Costs Equal One and a Half Times Sales
"We have strengthened our commercial organization and leadership, made progress across key long-term growth initiatives, and taken decisive actions to align our cost structure with our priorities," Mottiwala said. Yet third-quarter operating expenses of $36.6 million were unchanged from a year ago while revenue dropped 19%.
By our math, sales and overhead costs jumped 21.3 percentage points of revenue to 111.5%, and research spending rose 7.6 percentage points to 37.5%. Together, operating expenses reached 149.2% of product sales, widening the operating loss by 52% to $18.5 million.
What to watch: fourth-quarter sales and overhead spending after the recent staff cuts. Unless quarterly operating costs fall well below $36.6 million, doubling the sales team will widen losses further.
Risks this quarter didn't answer
Several standing concerns and watch items got no numbers in the third-quarter press release.
- Machine placements and installed base: omitted from the release after falling to 12 placements in the second quarter; the quarterly filing will show whether the base of 1,166 machines grew.
- Financial outlook and targets: management gave no forecast after pulling its 2026 targets in August, and the release set no numerical milestones for the turnaround before early 2027.
- Alcon overlap: no disclosure on whether the lenses developed with Alcon will compete for the same cataract patients as RxSight's own LAL.
- Share dilution: basic share count rose 1.8% from a year ago to 41.7 million, with $7.6 million in quarterly stock compensation.
👓 Other Themes
RxSight Restructured to Fund Its Sales Push
To pay for doubling its U.S. sales reps without increasing total spending, RxSight completed an organizational restructuring during the third quarter. Management said the shake-up will "better align resources with strategic priorities and drive meaningful operating expense savings in the core business". The release did not state the severance cost or the dollar target for annual savings.
💲 Other KPIs
Cash and short-term investments rose by $45.9 million from June after Alcon paid its $60 million upfront fee. Excluding that payment, the business burned about $14.1 million in cash during the quarter by our math, compared with $9.8 million in the second quarter.
Excluding $7.6 million of stock-based pay, the net loss widened fivefold from a year ago to $8.6 million, or $0.21 per share, compared with $0.04 a year earlier and $0.11 in the second quarter. Lower lens volume and inventory write-downs drove the deeper loss.
Uncollected customer bills fell 29.6% from a year ago and 8.2% from June. Receivables shrank faster than the 19.1% drop in product sales, showing that clinics are paying their bills on time despite ordering fewer lenses.
❓ Key Questions
How many LDD machines did clinics install in Q3?
The press release left out LDD unit sales and the total installed base after placements dropped to 12 last quarter. Without the machine count, investors cannot tell if clinic returns have started to shrink the installed base.
How much will the restructuring save, and what did it cost?
Management said the third-quarter restructuring will fund a near-doubling of the U.S. sales force. Naming the dollar savings and severance charges would show whether total operating expenses can actually stay flat next year.
Will Alcon's adjustable lenses sell to the same cataract patients?
Alcon will pay a 30% royalty on lenses built with RxSight's technology, while RxSight earns a 73.6% gross margin selling its own lenses. Management has not explained how it will keep Alcon from taking its existing customers.
How much of the $39.6 million inventory is close to expiring?
Inventory has climbed 37% over the past year while lens sales dropped 11%, and higher inventory reserves cut third-quarter gross margin by more than six points. Breaking out aging stock would show when these write-downs will end.